News Releases
May 10, 2021
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma Read more
Apr 21, 2021
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer Read more
Apr 5, 2021
ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148 Read more
Mar 18, 2021
ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones Read more
Mar 15, 2021
ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors Read more
Mar 4, 2021
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics Read more
Mar 2, 2021
ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference Read more
Jan 11, 2021
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021 Read more
Jan 5, 2021
ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference Read more